Anemia in children with chronic kidney disease

Pediatric Nephrology

Volumn 23, Issue 2, 2008, Pages 209-219

  Koshy, Susan M ^a   Geary, Denis F ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Chronic kidney disease; Erythropoietin; Hemoglobin; Iron; Pediatric

Indexed keywords

ANTACID AGENT; ASCORBIC ACID; CALCIUM; CARNITINE; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FOLIC ACID; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; IRON; IRON DEXTRAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMEPRAZOLE; PHOSPHATE BINDING AGENT; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; ANAPHYLAXIS; ANEMIA; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BONE MARROW EXAMINATION; BRAIN ISCHEMIA; CHRONIC KIDNEY DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; HEALTH CARE ORGANIZATION; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE PAIN; IRON DEFICIENCY ANEMIA; IRON THERAPY; LABORATORY TEST; NAUSEA; NEPHROLOGIST; OXALOSIS; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; SECONDARY HYPERPARATHYROIDISM; THROMBOCYTOSIS; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ANEMIA; CHILD; CHILD, PRESCHOOL; DIETARY SUPPLEMENTS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; INFANT; IRON COMPOUNDS; MALE; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 38349082674     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0381-2     Document Type: Article

References (81)

1. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D (1999) Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34:125-134
2. Morris KP, Skinner JR, Hunter S, Coulthard MG (1994) Cardiovascular abnormalities in end stage renal failure: The effect of anaemia or uraemia? Arch Dis Child 71:119-122
3. Morris KP, Sharp J, Watson S, Coulthard MG (1993) Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia. Arch Dis Child 69:580-586
4. Jabs K (1996) The effects of recombinant human erythropoietin on growth and nutritional status. Pediatr Nephrol 10:324-327
5. Chavers BM, Roberts TL, Herzog CA, Collins AJ, St Peter WL (2004) Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int 65:266-273
6. Wong H, Mylrea K, Feber J, Drukker A, Filler G (2006) Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int 70:585-590
7. K/DOQI; National Kidney Foundation (2006) III Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Children. Am J Kidney Dis 47(Suppl 3):S86-108
8. Behrman RE, Kliegman R, Jenson HB (2000) Nelson textbook of pediatrics, 16th edn. W.B. Saunders Company, Collingwood, Ontario
9. Beutler E, Waalen J (2006) The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration. Blood 107:1747-1750
10. Hollowell JG, Van Assendelft OW, Gunter EW, Lewis BG, Najjar M, Pfeiffer C (2005) Hematological and iron-related analytes - reference data for persons aged 1 year and over: United States, 1988-1994. National Center for Health Statistics. Vital Health Stat 11:1-156
11. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW (1984) Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25:437-444
12. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78
13. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimizu T, Miyake T (1985) Isolation and characterization of genomic cDNA clones of human erythropoietin. Nature 313:806-810
14. Lin FK, Suggs S, Lin CH, Browne JK, Smailing R, Egric JC, Chen KK, Fox GM, Martin F, Stabinsky Z, Badrawi SM, Lai PH, Goldwasser E (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82:7580-7584
15. Fisher JW (2003) Erythropoietin: Physiology and pharmacology update. Exp Biol Med 228:1-14
16. Koury MJ, Bondurant MC (1992) The molecular mechanism of molecular erythropoietin production. Eur J Biochem 210:649-666
17. Donnelly S (2001) Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis 38:415-425
18. Besarab A, Frinak S, Yee J (1999) An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 10:2029-2043
19. Ly J, Marticorena R, Donnelly S (2004) Red blood cell survival in chronic renal failure. Am J Kidney Dis 44:715-719
20. Muller-Wiefel DE, Sinn H, Gilli G, Scharer K (1977) Hemolysis and blood loss in children with chronic renal failure. Clin Nephrol 8:481-486
21. Gillespie RS, Wolf FM (2004) Iron therapy in pediatric hemodialysis patients: A meta-analysis. Pediatr Nephrol 19:662-666
22. Morgan HE, Gautam M, Geary DF (2001) Maintenance intravenous iron therapy in pediatric hemodialysis patients. Pediatr Nephrol 16:779-783
23. Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986-1995
24. Macdougall IC, Cooper AC (2002) Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17[Suppl 11]:39-43
25. Pereira BJ (1995) Balance between pro-inflammatory cytokines and their specific inhibitors in patients on dialysis. Nephrol Dial Transplant 10[Suppl 7]:27-32
26. Nomura S, Ogawa Y, Osawa G, Katagiri M, Harada T, Nagahana H (1996) Myelofibrosis secondary to renal osteodystrophy. Nephron 72:683-687
27. Rosenlof K, Fyhrquist F, Tenhunen R (1990) Erythropoietin, aluminium, and anaemia in patients on hemodialysis. Lancet 335:247-249
28. Roger SD, Macdougall IC, Thuraisingham RC, Raine AE (1991) Erythropoietin in anemia of renal failure in sickle cell disease. N Engl J Med 325:1175-1176
29. Cheng IK, Lu HB, Wei DC, Cheng SW, Chan CY, Lee FC (1993) Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. Am J Nephrol 13:142-148
30. Hess E, Sperschneider H, Stein G (1996) Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? Nephrol Dial Transplant 11:749-751
31. Lu R, Foerster J, Lukens J, Paraskevas F, Greer JP (1999) Wintrobe's clinical hematology, 10th edn. Lippincott Williams and Wilkins, Philadelphia
32. Henry JB (1996) Methods hematology: Basic methodology in clinical diagnosis and management by laboratory methods, 19th edn. Saunders, Philadelphia
33. Holt JT, DeWandler MJ, Aevan DA (1982) Spurious elevation of electronically determined mean corpuscular volume and hematocrit caused by hyperglycemia. Am J Clin Pathol 77:561-567
34. Adamson JW (1999) Normal iron physiology. Semin Dialysis 12:219-223
35. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK (1996) The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7:2654-2657
36. Mittal S, Maesaka JK, Fishbane S (1999) Diagnosis of iron deficiency in end stage renal disease. Semin Dial 12:231-234
37. Frankenfield DL, Neu AM, Warady BA, Fivush BA, Johnson CA, Brem AS (2003) Anemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project. Kidney Int 64:1120-1124
38. Braun J (1999) Erythrocyte zinc protoporphyrin. Kidney Int 55[Suppl 69]:S57-S60
39. Thomas C, Thomas L (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48:1066-1076
40. Chiang WC, Tsai TJ, Chen YM, Lin SL, Hsieh BS (2002) Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol 58:363-369
41. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Coates PM (1986) Effective human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 2:1175-1178
42. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW (1989) Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163
43. Casati S, Passerini P, Campise MR, Graziani G, Cesana E, Ponticelli C (1987) Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having hemodialysis. N Engl J Med 295:1017-1020
44. Sinai-Trieman L, Salusky IB, Fine RN (1989) Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis. J Pediatr 114:550-554
45. Offner G, Hoyer PF, Latta K, Winkler L, Brodehl J, Scigalla P (1990) One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis. Pediatr Nephrol 5:498-500
46. Provenzano R, Bhaduri S, Singh AK (2005) Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The prompt study. Clin Nephrol 2:113-123
47. North American Pediatric Renal Transplant Cooperative Study Registry Report (2004) https://web.emmes.com/study/ped/annlrept/annlrept.html
48. Port RE, Kiepe D, Van Guilder M, Jelliffe RW, Mehls O (2004) Recombinant human erythropoietin for the treatment of renal anaemia in children: No justification for bodyweight-adjusted dosage. Clin Pharmacokinet 43:57-70
49. MacDougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J (1999) Pharmacokinetics of novel erythropoesis-stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392-2395
50. Lerner G, Kale AS, Warady BA, Jabs K, Bunchman TE, Heatherington A (2002) Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol 11:933-937
51. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C (2002) Randomized control trial of Darbepoetin Alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40:110-118
52. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ (2001) Novel erythropoesis-stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60:741-747
53. DePalo P, Giordanno M, Palumbo F, Bellantuono R, Messina G, Colella V, Caringella AD (2004) Clinical experience with Darbepoetin Alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 3:337-340
54. Geary DF, Keating LE, Vigneux A, Stevens D, Hébert D, Harvey EA (2005) Darbepoetin Alfa (Aranesp) in children with chronic renal failure. Kidney Int 4:1759-1765
55. Durkan AM, Keating LE, Vigneux A, Geary DF (2006) The use of Darbepoetin in infants with chronic renal impairment. Pediatr Nephrol 5:694-697
56. Casadevall N, Nataf J, Viron B, Colta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:46-475
57. Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM (2005) Long term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin; a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 106:3343-3347
58. Casadeall N, Eckardt KU, Rossert J (2005) Epoetin induced autoimmune pure red cell aplasia. J Am Soc Nephrol 16:S67-S69
59. Fishbane S, Maesaka JK (1997) Iron management in end-stage renal disease. Am J Kidney Dis 29:319-333
60. Fishbane S (1998) Iron treatment: Impact of safety issues. Am J Kidney Dis 32[Suppl 4]:S152-S156
61. Jensen RT (2006) Consquences of long-term proton pump blockage: Insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 98:4-19
62. Ruiz-Jaramillo Mde L, Guizar-Mendoza JM, Gutierrez-Navarro Mde J, Dubey-Ortega LA, Amador-Licona N (2004) Intermittent versus maintenance iron therapy in children on hemodialysis: A randomized study. Pediatr Nephrol 19:77-81
63. Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara (2004) Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 19:655-661
64. Warady BA, Zobrist RH, Wu J, Finan E (2005) Ferrlecit Pediatric Study Group. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 20:1320-1327
65. Novey HS, Pahl M, Haydik I, Vaziri ND (1994) Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy 72:224-228
66. Agarwal R, Vasvada N, Sachs NG, Chase S (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279-2289
67. Fletes R, Lazarus M, Gage J, Chertow GM (2001) Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 37:743-749
68. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J (1996) The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:529-534
69. Faich G, Strobos J (1999) Sodium ferric gluconate complex in sucrose: saferintravenous iron therapy than iron dextrans. Am J Kidney Dis 33:464-470
70. Berard E, Iordache A (1992) Effect of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children: about two cases. Nephron 62:368-369
71. Lilien MR, Duran M, Quak JM, Frankhuisen JJ, Schroder CH (2000) Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis. Pediatr Nephrol 15:17-20
72. Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C (1995) Resistance to erythro-poietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 10[Suppl 6]:44-47
73. Deira J, Diego J, Martinez R, Oyarbide A, Gonzalez A, Diaz H, Grande J (2003) Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. J Nephrol 16:703-709
74. Keven K, Kutlay S, Nergizoglu G, Erturk S (2003) Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 41:1233-1239
75. Bamgbola OF, Kaskel F (2005) Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr Nephrol 20:1622-1629
76. Rossert J, Fouqueray B, Boffa JJ (2003) Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 14[Suppl 2]:S173-S177
77. Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF (2000) Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 14:898-902
78. Warady BA, Ho M (2003) Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 18:1055-1062
79. Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, Zelikovsky N (2004) Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 44:1017-1023
80. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Eng J Med 339:584-590
81. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D (2005) Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16:2180-2189